was performed. The primary outcome was time to development of CCA and our goal was to determine whether the risk differed between patients with and without colectomy. Risk factors were assessed using univariable and multivariable Cox proportional hazard models where colectomy, IBD disease duration, and development of advanced liver disease were treated as timedependent covariates.
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that can progress to cirrhosis and liver failure ( 1 ) . PSC frequently coexists with infl ammatory bowel disease (IBD), particularly ulcerative colitis ( 2 ) . Compared with patients with IBD alone, individuals with PSC-IBD are at an increased risk of developing colonic dysplasia or neoplasia at a rate that approaches a lifetime risk of up to 25%, thereby mandating close surveillance with
Duration of Infl ammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients
With Primary Sclerosing Cholangitis and IBD colonoscopy and biopsies annually from the time of diagnosis ( 3, 4 ) . Patients with IBD who develop colonic dysplasia, carcinoma, or medically refractory disease oft en require surgical intervention, usually with colectomy and ileal pouch anal anastomosis.
Along with an increased risk of colorectal cancer, patients with PSC with or without IBD are also at increased risk of primary hepatobiliary neoplasia and, in particular, cholangiocarcinoma (CCA). Th e lifetime incidence of CCA in patients with PSC ranges between 5 and 10%, with the mean age of diagnosis in the fourth decade of life ( 5 ) . Although curative options are available for limited-stage disease, CCA is frequently detected in its advanced stages when prognosis is poor, and thus predictors of CCA development remain critically needed to identify at-risk patients.
Th e risk factors for CCA in PSC have been reported, although none are suffi ciently robust or reliable enough to alter recommendations for disease surveillance ( 6, 7 ) . As a consequence, major international societies have not made specifi c recommendations for surveillance of CCA in patients with PSC, but acknowledge that, given the prognostic implications of this diagnosis, many clinicians will off er surveillance with an imaging study and carbohydrate antigen at yearly intervals ( 8, 9 ). An increased risk of CCA among patients with chronic IBD and proctocolectomy has been suggested, but this risk remains ill-defi ned ( 10, 11 ) . Identifying robust risk factors associated with CCA among patients with PSC is important to allow clinicians to risk stratify patients and guide surveillance strategies. Th erefore, we sought to characterize the association between CCA, IBD disease duration, and colectomy in a large cohort of patients with PSC-IBD.
METHODS

Study design
Patients diagnosed with PSC-IBD and seen at the Mayo Clinic in Rochester, Minnesota, between January 2005 and May 2013 were identifi ed for this retrospective study. Eligible subjects were identifi ed through a search of the electronic medical record using the terms "primary sclerosing cholangitis" or "PSC. " Th e diagnosis of PSC was based on accepted criteria, including biochemical and cholangiographic features ( 12 ) , and IBD was diagnosed based on characteristic endoscopic and/or histopathologic fi ndings. Patients met inclusion criteria for the study if they had a confi rmed diagnosis of both PSC and IBD, were >18 years of age, and who underwent cross-sectional imaging of the abdomen and endoscopic retrograde cholangiopancreatography (ERCP).
Study variables
Medical records including clinical notes, laboratory tests, and radiographic, endoscopic, and pathologic studies were reviewed for confi rmation of diagnosis and to characterize disease course. Demographic data including age and gender were recorded. Dates of PSC and IBD diagnosis and complications of each disease were documented. Need for colectomy as well as date, type, and indication for surgery were noted. Indication for colectomy was recorded as refractory disease, neoplasia, or unknown reasons. Neoplasia included low-grade dysplasia, high-grade dysplasia, or confi rmed adenocarcinoma. Th ose patients who required a colectomy for both active disease and neoplasia were considered to have neoplasia as their primary surgical indication.
Complications of PSC including CCA, advanced liver disease (defi ned as presence of gastroesophageal varices, ascites, or encephalopathy), and need, date, and indication for liver transplantation (either end-stage liver disease or CCA) were also recorded. CCA was diagnosed based on defi nitive histopathology from resection, biopsy, or cytology specimens or based on characteristic cross-sectional imaging features ( 13 ) . Smoking history and use of ursodeoxycholic acid as noted in the medical record were also documented. Th e study was approved by the Mayo Clinic Institutional Review Board.
Statistical analysis
Descriptive statistics were used to defi ne the baseline characteristics of the cohort. Qualitative variables were summarized as proportions and continuous variables as means with s.d. Th e primary analysis assessed whether time to development of CCA diff ered between PSC-IBD patients who had or had not undergone colectomy. Risk factors for CCA were assessed using univariable and multivariable Cox proportional hazard models where colectomy, IBD disease duration, and development of advanced liver disease were treated as time-dependent covariates. Models were constructed using age as the timescale that adjusts for an age eff ect. All PSC-IBD patients with a clinic visit during the January 2005 to May 2013 observation period were initially included in the study. To minimize immortal time bias, risk assessment started in 2005 or following diagnosis of both PSC and IBD if aft er 2005; thus, only patients who were alive and without an outcome by this date were included in the analysis. Th e observation period for included subjects was censored at development of an end point (i.e., death, liver transplantation, or CCA) or at date of last clinical follow-up. IBD duration was defi ned as date of diagnosis to date of end point or last clinical follow-up and was calculated from date of diagnosis to the point of entry into the study with the analysis timescale and IBD duration measured in years and IBD duration considered as a linear term. A linear relationship between IBD duration and CCA risk was confi rmed. IBD duration was not censored at colectomy. To further investigate the infl uence of colectomy on CCA risk, we considered a Cox model that included IBD duration, colectomy, and the interaction between the IBD duration and colectomy. Th is model allowed an estimate of whether the infl uence of IBD duration on time to development of CCA changed before and aft er colectomy. A signifi cant interaction term would suggest that the infl uence of IBD duration on CCA was modifi ed aft er colectomy. A sensitivity analysis for the primary end point was performed in a combined cohort including the PSC-IBD patients with ERCP and a random sample of two-thirds of all PSC-IBD patients without ERCP seen during the same study period. Case weights were used allowing the sampled patients without ERCP to represent all patients without ERCP seen during the study period. CCA rates were calculated by colectomy, age, and follow-up time-specifi c person-years. Th e relationship of CCA rate vs. age and time since diagnosis was modeled using a smoothing spline within a gener-
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alized additive model assuming a Poisson error distribution and displayed graphically using the predicted values.
RESULTS
Patient characteristics
During the study period, 407 patients with PSC-IBD were evaluated at the Mayo Clinic, Rochester, and were eligible for the study. Aft er exclusion of patients with missing diagnosis dates or follow-up information and those who had reached an end point before 2005, 399 patients with PSC-IBD were included in the fi nal analysis. Of this cohort, 67% ( n =268) were male and 33% ( n =131) were female. Th e mean follow-up was 9.4±7.9 years aft er PSC-IBD diagnosis. IBD was diagnosed a mean of 10.5±12.0 years before PSC. Most patients (86%, n =343) had ulcerative colitis as the phenotypic manifestation of IBD, 13% ( n =50) had Crohn's disease, and 2% ( n =6) had indeterminate colitis. Of the 399 patients, 34% ( n =137) had a colectomy, of whom a majority (70%, n =94) had an ileal pouch anal anastomosis. Th e indication for colectomy was colonic neoplasia in 45% ( n =61), medically refractory disease in 37% ( n =51), and not available in the medical record in 18% ( n =25) of patients.
CCA occurred in 31% ( n =123) of patients in the cohort. Diagnosis was based on defi nitive histology alone in 24% ( n =29), consistent radiographic fi ndings in 23% ( n =28), and both histology and imaging in 51% ( n =63). Advanced liver disease was present in 39% ( n =156) of patients overall and 35% ( n =43) of patients who developed CCA. Varices were the most common manifestation and were found in 86% ( n =134). One-quarter of patients ( n =99) underwent liver transplantation, with 54% ( n =53) of them having a primary indication of CCA. Additional clinical characteristics of the cohort are summarized in Tables 1 and 2 .
Of the 399 included patients, 51% ( n =203) had an event (i.e., CCA, liver transplantation, and/or death) and 49% ( n =196) did not. We were able to ascertain clinical status on or aft er 1 January 2013 in 89% ( n =355) of the entire cohort and 78% ( n =152) of those who were free of an event ( Figure 1 ).
Overall rate of CCA diagnosis
Th e absolute risk of CCA increased with age and was higher in those patients who had a colectomy compared with those who did not ( Figure 2a ). In patients 0-29 years, 30-39 years, 40-49 years, 50-64 years, and 65+ years of age who did not have a colectomy, the rate of CCA was 9.9, 48.9, 64.2, 67.6, and 37.3 per 1,000 person-years, respectively, compared with 61.5, 67.4, 84.0, 89.3, and 95.8 per 1,000 person-years, respectively, among those who did have a colectomy. Th e rate of CCA from time of PSC-IBD diagnosis was also higher in those who had a colectomy compared with those who did not ( Figure 2b ) and rates were highest in the fi rst 5 years aft er diagnosis of PSC-IBD.
Impact of colectomy on CCA risk
CCA was diagnosed in 39% ( n =53) of patients who had a colectomy compared with 27% ( n =70) of patients who did not have a colectomy. Considering the entire cohort of 399 patients, univariate age-adjusted Cox proportional hazard models revealed that colectomy ( P =0.02) and duration of IBD ( P <0.01) were signifi cantly associated with an increased risk of CCA. In addition, the presence of colonic dysplasia or neoplasia ( P =0.06) and colectomy performed for an indication of colonic neoplasia ( P =0.05) were suggestive of increased CCA risk ( Table 3 ). Aft er adjusting for IBD duration, none of the other risk factors remained statistically associated with CCA ( Supplementary Table S1 online). Moreover, on multivariable analysis, duration of IBD remained signifi cantly associated with an increased risk of CCA with a hazard ratio (HR) of 1.33 (95% confi dence interval (CI) 1.11-1.60, P <0.01). Not surprisingly, IBD duration was also associated with an increased risk of colectomy (HR 1.41, 95% CI 1.10-1.82, P <0.01) in the cohort. A random sample of an additional 186 PSC-IBD patients without ERCP who were evaluated during the study period were also assessed, and aft er exclusion of patients with missing data a sensitivity analysis including 157 patients supported the association between duration of IBD and increased risk of CCA (HR 1.53, 95% CI 1.30-1.80, P <0.001). Analysis of the interaction between IBD duration and colectomy on risk of CCA demonstrated that there was no evidence to suggest that the infl uence of IBD duration on CCA changed aft er colectomy Gulamhusein et al.
( P =0.69), suggesting that the increased risk persists despite surgical "cure" of colonic disease.
Impact of indication for colectomy
Th e risk of CCA diff ered between those who had a colectomy for neoplasia compared with those whose primary indication was medically refractory disease. Compared with those without colectomy, the HR for CCA in patients with colectomy for colonic neoplasia was 1.62 (95% CI 1.01-2.61, P =0.05). In contrast, the risk of CCA was not signifi cantly increased among patients who had colectomy for medically refractory disease compared with those Th e pathobiological mechanisms underlying our fi ndings remain unclear but may be related to the altered bile acid milieu or altered microbiome ( 17, 18 ) and metabolome (19) (20) (21) that exist in a chronically infl amed colon and can persist aft er colectomy. Altered bile acid profi les in the setting of chronic IBD and aft er colectomy have been reported (22) (23) (24) , and whether these changes could injure the biliary epithelia via the enterohepatic circulation or modify the biliary microenvironment to promote malignant transformation remains plausible, although unconfi rmed. Changes to the gut microbiome in the setting of colonic infl ammation ( 25, 26 ) and with colectomy ( 18 ) have also been reported; but whether these changes could result in downstream eff ects on biliary epithelia leading to carcinogenesis remains to be determined. Recently, Duboc et al. ( 27 ) observed altered fecal bile acid profi les and dysbiosis of the microbiome in patients with active IBD compared with those with quiescent disease and healthy controls. How these changes could aff ect PSC and its complications remain a ripe area for future study. Finally, given the association between colonic neoplasia and CCA in our study, it is important to consider the possibility of a shared genetic predisposition toward developing cancer in these patients who seem to be particularly susceptible to developing malignant disease. Future eff orts should investigate whether genes regulating tumor development and growth are somehow defective at the genomic level or altered by other nongenomic mechanisms in these patients.
At our center, we do not have a standardized approach for CCA surveillance specifi c to patients with PSC-IBD; although, in general, all patients with PSC with and without IBD undergo surveillance for hepatobiliary neoplasia with yearly cross-sectional imaging (usually magnetic resonance cholangiopancreatography) and CA 19-9. Although this approach is mentioned by international societies as being employed by many clinicians, it is not formally recommended because of the lack of a robust evidence base. It is unlikely that that this monitoring strategy alone infl uenced our results to a signifi cant degree as this surveillance approach is not specifi c to the subset of PSC-IBD patients, nor specifi c to our center. Rather, the large number of events in our cohort likely refl ects the nature of our referral practice; though consequently, it also allowed for adequate statistical power to identify this subset of PSC patients who are at a particularly high risk of CCA. In our multivariable model, duration of IBD was the only independent predictor of increased risk of CCA with a 33% increased risk per 10 years of IBD. Furthermore, in the subset of PSC-IBD patients with colectomy, those having surgery with an indication of colonic neoplasia were at a signifi cantly higher risk of CCA relative to those who had colectomy for refractory disease (HR 2.68, 95% CI 1.01-7.07), even aft er adjustment for IBD disease duration. Th us, targeted structured surveillance strategies in these high-risk subgroups (namely, those with prolonged IBD and those with colectomy done for colonic neoplasia) may be an appropriate strategy.
with an intact colon (HR 0.67, 95% CI 0.32-1.41, P =0.29). When the age-adjusted analysis was limited to just those patients with colectomy, a signifi cantly increased risk of CCA was seen among those with a colectomy for colonic neoplasia compared with those with colectomy for medically refractory disease (HR 2.91, 95% CI 1.24-6.84, P =0.01). Repeating the analysis starting at 1 year aft er colectomy to exclude patients with potentially prevalent CCA (i.e., subclinical CCA already existing at the time of colectomy), a signifi cantly increased risk of CCA remained among patients with colectomy for neoplasia (HR 2.94, 95% CI 1.25-6.94, P =0.01). Aft er adjusting for IBD duration in the subset of patients who had surgery, colectomy for colonic neoplasia approached signifi cance (HR 2.68, 95% CI 1.01-7.07, P =0.05). Th e type of colectomy did not seem to infl uence the risk of CCA. Patients with ileal pouch anal anastomosis did not have a signifi cantly diff erent risk of CCA compared with patients with any other surgical procedure (HR 0.68, 95% CI 0.34-1.35, P =0.27).
DISCUSSION
To our knowledge, this is the largest study to date examining risk factors for CCA in patients with PSC and the only study to specifi cally address this risk in patients with PSC-IBD. Our results demonstrate that prolonged duration of IBD is associated with an increased risk of CCA in patients with PSC-IBD. We also demonstrate that colectomy, and in particular colectomy performed for colonic neoplasia or dysplasia rather than medically refractory disease, is associated with an increased risk of CCA, in keeping with the known association between IBD duration, colectomy, and colonic neoplasia. An additional novel observation was that the risk of CCA was not modifi ed aft er colectomy, suggesting that colonic resection itself does not ameliorate the risk of CCA associated with prolonged IBD disease duration.
Th e fi ndings of this study are consistent with previous reports from smaller cohorts. For example, in their study of 161 patients with PSC, Burak et al. ( 10 ) found an increased risk of CCA in patients undergoing colectomy on univariate but not multivariate analysis. Furthermore, in their cohort of 58 patients, Broome et al. ( 14 ) identifi ed an increased risk of CCA among patients with PSC and associated colonic dysplasia or carcinoma. In contrast, in a larger Scandinavian cohort, Boberg et al. ( 11 ) did not fi nd an increased risk of CCA among patients with colectomy ( P =0.48) or colon cancer ( P =0.25), although prolonged IBD duration was indeed found to be associated with increased CCA risk. Th ese diff erences may be explained by the relatively small number of patients with colectomy ( n =83) and CCA ( n =48) in the said study as compared with our cohort.
Th e clinical implications of these fi ndings are signifi cant given the age of onset of IBD, the lifetime risk of colectomy, the poor prognosis associated with CCA, and the paucity of reliable predictors available to identify patients at increased risk of this complication. Despite medical advances, ∼ 30-40% of patients with ulcerative colitis ultimately require surgery at some time during their disease course, and ∼ 10% of patients with Crohn's colitis eventually require large bowel resection ( 15 Th e strength of our study includes the large well-defi ned patient cohort with clearly defi ned outcomes. Our fi ndings are consistent with previous reports that have suggested an association between chronic IBD, colectomy, and CCA and refi ne the existing body of literature by focusing on patients with PSC and coexisting IBD.
We expand on current knowledge by demonstrating that neoplasia as an indication for colectomy confers a particularly increased risk of CCA; and importantly, colectomy itself does not appear to modify the increased risk of CCA associated with prolonged IBD disease duration.
Th e limitations of the study include the possibility of referral bias given the increased likelihood of patients with severe and complicated disease being seen in specialized centers; our center in particular manages a high volume of patients with CCA. In addition, this cohort included PSC-IBD patients who underwent ERCP, thus representing a selected population of PSC patients. Th e ERCP criterion was originally included as a means of identifying all histologically confi rmed events. ERCP is generally reserved for PSC patients with symptoms, rising levels of CA-19-9, and/or imaging evidence of dominant strictures ( 10 ) . At our center, ∼ 60% of patients fulfi ll these criteria, thus still representing a very signifi cant subset of PSC patients as a whole. Th is is consistent with the literature that suggests that 36-57% of patients with PSC develop a dominant stricture during their disease course ( 1 ) . To address this, we performed a sensitivity analysis that also included PSC patients without ERCP, and this also demonstrated a statistically higher risk of CCA with increasing duration of IBD, supporting the conclusion that IBD duration is an independent predictor of CCA risk in the full spectrum of patients with PSC-IBD. Despite the high prevalence of CCA in our cohort, we are reassured by other studies that have previously suggested similar associations. By analyzing all variables together in one large cohort, our study clarifi es that duration of IBD is a risk factor that independently increases CCA risk and this variable may infl uence the previously identifi ed associations between CCA, colectomy, and colonic neoplasia. Finally, data were also limited to what was available in the medical record, and this could aff ect results through inadequately reported variables and confounders. For example, the indication for colectomy was unavailable in 18% ( n =25) of patients, and whether knowledge of the reason for surgery in these patients would aff ect the strength of identifi ed associations is unknown. Th ese patients may refl ect the referral bias of the cohort as 88% ( n =22) had colectomies performed at other centers and were referred to Mayo Clinic with either concern for CCA or complications of PSC such as biliary obstruction with challenging ERCP. Furthermore, of these patients, 86% had their colonic surgery before 1998 (range 1957-1998); thus suggesting prolonged IBD disease duration. In fact, the median duration of IBD was signifi cantly longer in patients with an unknown indication for colectomy compared with those with colonic neoplasia and refractory disease (23.0 years vs. 12.9 years vs. 3.5 years, respectively, P <0.01). Th ese factors together likely contribute to the increased risk of CCA in patients with unknown indications for colectomy in our unadjusted and adjusted models ( Supplementary Table S1 ).
Based on our fi ndings, prolonged IBD disease duration is associated with an increased risk of CCA in patients with PSC-IBD and this risk persists aft er colectomy. Th is defi nes a patient population who may benefi t from close interval surveillance for hepatobiliary neoplasia with cross-sectional imaging and serologic testing (e.g., . Patients who have colectomy, particularly with the indication of colorectal neoplasia or dysplasia, are also at an increased risk and warrant close surveillance. Identifying patients with early CCA has signifi cant prognostic implications as curative treatment options such as liver transplantation are only available for earlystage disease. Future studies identifying the mechanisms underlying the association between IBD duration, colectomy, colonic dysplasia, and CCA will be valuable in further understanding the pathobiology of this devastating complication.
